BRPI0709506A2 - uso de uma composição que compreende uma quantidade eficaz de um rna de interferência (irna) que tem um cumprimento de 19 a 49 nucleotìdeos, uso de uma composição que compreende uma quantidade eficaz de um rna de interferência de um único cordão que tem um cumprimento de 19 a 49 nucleotìdeos, uso de uma composição que compreende uma molécula de sirna de cordão duplo que regula para baixo a expressão de um gene de syk através da interferência do rna e composição - Google Patents

uso de uma composição que compreende uma quantidade eficaz de um rna de interferência (irna) que tem um cumprimento de 19 a 49 nucleotìdeos, uso de uma composição que compreende uma quantidade eficaz de um rna de interferência de um único cordão que tem um cumprimento de 19 a 49 nucleotìdeos, uso de uma composição que compreende uma molécula de sirna de cordão duplo que regula para baixo a expressão de um gene de syk através da interferência do rna e composição Download PDF

Info

Publication number
BRPI0709506A2
BRPI0709506A2 BRPI0709506-6A BRPI0709506A BRPI0709506A2 BR PI0709506 A2 BRPI0709506 A2 BR PI0709506A2 BR PI0709506 A BRPI0709506 A BR PI0709506A BR PI0709506 A2 BRPI0709506 A2 BR PI0709506A2
Authority
BR
Brazil
Prior art keywords
seq
nucleotides
interfering rna
composition
mrna
Prior art date
Application number
BRPI0709506-6A
Other languages
English (en)
Portuguese (pt)
Inventor
John M Yanni
Jon E Chatterton
Daniel A Gamache
Steven T Miller
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI0709506A2 publication Critical patent/BRPI0709506A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0709506-6A 2006-04-13 2007-04-13 uso de uma composição que compreende uma quantidade eficaz de um rna de interferência (irna) que tem um cumprimento de 19 a 49 nucleotìdeos, uso de uma composição que compreende uma quantidade eficaz de um rna de interferência de um único cordão que tem um cumprimento de 19 a 49 nucleotìdeos, uso de uma composição que compreende uma molécula de sirna de cordão duplo que regula para baixo a expressão de um gene de syk através da interferência do rna e composição BRPI0709506A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79184706P 2006-04-13 2006-04-13
US60/791,847 2006-04-13
PCT/US2007/066619 WO2007121347A2 (en) 2006-04-13 2007-04-13 Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Publications (1)

Publication Number Publication Date
BRPI0709506A2 true BRPI0709506A2 (pt) 2011-07-19

Family

ID=38610402

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0709506-6A BRPI0709506A2 (pt) 2006-04-13 2007-04-13 uso de uma composição que compreende uma quantidade eficaz de um rna de interferência (irna) que tem um cumprimento de 19 a 49 nucleotìdeos, uso de uma composição que compreende uma quantidade eficaz de um rna de interferência de um único cordão que tem um cumprimento de 19 a 49 nucleotìdeos, uso de uma composição que compreende uma molécula de sirna de cordão duplo que regula para baixo a expressão de um gene de syk através da interferência do rna e composição

Country Status (13)

Country Link
US (4) US8048863B2 (enExample)
EP (3) EP2004240A4 (enExample)
JP (1) JP2009533475A (enExample)
KR (1) KR20080110900A (enExample)
CN (2) CN101972483A (enExample)
AR (1) AR060448A1 (enExample)
AU (2) AU2007238027B2 (enExample)
BR (1) BRPI0709506A2 (enExample)
CA (1) CA2649138C (enExample)
MX (2) MX345954B (enExample)
TW (2) TW200808360A (enExample)
WO (1) WO2007121347A2 (enExample)
ZA (1) ZA200808744B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144209A1 (pt) 2018-01-24 2019-08-01 Universidade Federal Do Rio Grande Do Sul Composição farmacêutica nanométrica de liberação de moléculas de rna de interferência e uso da mesma

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008308784B2 (en) * 2007-10-01 2013-07-18 Arrowhead Research Corporation Self complementary AAV-mediated delivery of interfering RNA molecules to treat or prevent ocular disorders
EP2306993B1 (en) * 2008-05-26 2014-03-12 Universität Zürich Protamine/rna nanoparticles for immunostimulation
CN106344495A (zh) * 2008-12-22 2017-01-25 奥德纳米有限公司 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
CN104805085A (zh) * 2014-01-29 2015-07-29 江苏命码生物科技有限公司 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用
HK1244030A1 (en) * 2014-12-29 2018-07-27 东丽株式会社 Composition containing nucleic acid molecule stably
WO2016192741A1 (en) 2015-05-29 2016-12-08 Ablacon Inc. Elongated medical device suitable for intravascular insertion, optical force sensing assembly for an elongated medical device and method of making a medical optical force sensing assembly
EP3369816B1 (en) * 2015-10-30 2024-03-13 Toray Industries, Inc. Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-beta1 gene

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360720A (en) * 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
EP0831875A4 (en) * 1995-06-07 2002-07-31 Univ Pennsylvania METHODS OF INHIBITING PHAGOCYTOSIS
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
EP1627061B1 (en) * 2001-05-18 2009-08-12 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
EP1554407B1 (en) * 2002-10-01 2009-07-29 Epigenomics AG Method for the treatment of breast cell proliferative disorders
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
JP3839453B2 (ja) * 2002-11-22 2006-11-01 株式会社バイオシンクタンク Ｒｎａ干渉の標的塩基配列検索方法、ｒｎａ干渉を生じさせるポリヌクレオチドの塩基配列設計方法、２本鎖ポリヌクレオチドの作製方法、遺伝子の発現抑制方法、塩基配列処理装置、塩基配列処理方法をコンピュータに実行させるプログラム、記録媒体、および、塩基配列処理システム
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
WO2005007623A2 (en) * 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
WO2005049838A2 (en) 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
GB0404209D0 (en) 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
US20090005268A1 (en) * 2005-07-18 2009-01-01 Epigenomics Ag Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers
EP1960372B1 (en) * 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
UY31267A1 (es) 2007-08-03 2009-01-05 Alcon Res Ltd Inhibición del pasaje de senalización del tnfa relacionada con arni para el tratamiento de la angiogénesis ocular

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144209A1 (pt) 2018-01-24 2019-08-01 Universidade Federal Do Rio Grande Do Sul Composição farmacêutica nanométrica de liberação de moléculas de rna de interferência e uso da mesma

Also Published As

Publication number Publication date
US8865671B2 (en) 2014-10-21
US8048863B2 (en) 2011-11-01
TW201336514A (zh) 2013-09-16
AU2007238027A1 (en) 2007-10-25
KR20080110900A (ko) 2008-12-19
EP2004240A2 (en) 2008-12-24
ZA200808744B (en) 2009-12-30
AU2013207601B2 (en) 2016-11-17
CN101443020A (zh) 2009-05-27
AU2007238027B2 (en) 2013-08-15
US20090324507A1 (en) 2009-12-31
JP2009533475A (ja) 2009-09-17
US20110288157A1 (en) 2011-11-24
WO2007121347A3 (en) 2008-12-04
WO2007121347A2 (en) 2007-10-25
AR060448A1 (es) 2008-06-18
MX345954B (es) 2017-02-16
US20160257963A1 (en) 2016-09-08
EP2004240A4 (en) 2010-12-15
EP3156486A2 (en) 2017-04-19
US9371529B2 (en) 2016-06-21
MX2008013068A (es) 2008-12-16
CA2649138C (en) 2018-04-03
EP2662446A2 (en) 2013-11-13
EP3156486A3 (en) 2017-07-12
TW200808360A (en) 2008-02-16
US20140357695A1 (en) 2014-12-04
EP2662446A3 (en) 2014-04-02
CA2649138A1 (en) 2007-10-25
CN101972483A (zh) 2011-02-16

Similar Documents

Publication Publication Date Title
US8541389B2 (en) RNAi-mediated inhibition of tumor necrosis factor α-related conditions
US9371529B2 (en) RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
US9745585B2 (en) RNAi-mediated inhibition of histamine receptor H1-related conditions

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]